The phase III AEGEAN trial is a randomized, double-blind, placebo-controlled trial assessing the efficacy of neoadjuvant durvalumab plus chemotherapy followed by surgery and adjuvant durvalumab in patients with resectable non–small cell lung cancer (NSCLC). Results from the trial were presented by Heymach et al at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Abstract CT005).
